AKT1 and metastatic prostate carcinoma: For example, while enzalutamide is effective in treating advanced and metastatic prostate cancer,27, 44 therapeutic resistance and subsequent recurrence eventually occur after enzalutamide treatment,45, 46 and over‐activation of the PI3K/Akt pathway is often involved.47, 48